





Supplementary Figure 1

Cooperative AS function is required for pericyte-to-iN conversion.



a, Euler diagram shows number of DE genes of each condition (Ascl1-only, Sox2-only, AS) at 2 dpi. **b**, Bar graph representing number of direct Ascl1-targets transcriptionally upregulated across different conditions and timepoints. **c**, Euler diagram showing that the majority of direct Ascl1-targets are regulated by AS synergism in human brain pericytes at 2 and 7 dpi. **d**, Heatmap shows normalized expression (Z-score) of direct Ascl1-target genes upregulated in AS-transduced cells at 7 dpi. Note that only a minor fraction of these genes is also upregulated by Ascl1 alone. **e**, GO term analysis of DE genes for each condition at 2 dpi. Shown are the 10 most significantly regulated GO terms. GO terms were ordered according to their significance as determined by Fisher's exact test; n = 3 individual pericyte donors per experimental group. **f**, GO term analysis of DE genes for each condition at 7 dpi. Significantly regulated genes in GO categories are contained in Supplementary Table 2. GO terms were ordered according to their significance as determined by Fisher's exact test; n = 3 individual pericyte donors per experimental group. **g**, tSNE plots from the analysis of Ascl1-only and AS transduced cells at 2 and 7 dpi from Fig. 1e are colored based on the expression of selected pericyte genes (Log₂ FPKM). **h**, tSNE plots from the analysis of Ascl1-only and AS transduced cells at 2 and 7 dpi from Fig. 1e are colored based on the expression of selected mesoderm, neurogenesis-related, and GABAergic signature genes (Log₂ FPKM).



Supplementary Figure 2

Expression of pericyte heterogeneity genes.


a, tSNE plot from Fig. 2a colored based on the expression of selected genes enriched in different pericyte groups. **b**, Violin plots show the density expression distribution of genes in pericyte group 1 (31 cells) and group 2 (44 cells). **c**, GO term analysis of pericyte heterogeneity genes from Fig. 2b; group 1, n = 31 cells; group 2, n = 44 cells; GO terms were ordered according to their significance as determined by Fisher's exact test. **d**, Representative flow cytometry plot showing isotype control for the sorting of LEPR-positive cultured human pericytes (Fig. 2f); n = 4.



Supplementary Figure 3

Switch genes are expressed in the germinal zones of the developing CNS.

a In situ hybridization images (GenePaint.org) show the expression of selected switch genes in the developing mouse forebrain (E14.5). **b** Projecting the switch gene signature onto published scRNA-seq data¹ reconstructing the MEF-to-iN reprogramming path (259 cells) shows the high base level in the starting MEF population and downregulation of the switch gene signature along differentiation towards iNs. Shaded gray represents 0.95 confidence interval.




Supplementary Figure 4

Characterization of ASD cells and shift towards a glutamatergic neuron phenotype by combinatorial expression of AS with Neurog2.

a, Summary of morphometric analyses showing significant differences between untreated and Dorsomorphin-treated AS cells. Data are shown as mean ± SEM; (untreated, n = 14 cells of 3 independent experiments; Dorsomorphin-treated, n = 14 cells of 3 independent experiments); two-tailed unpaired Student's t test; primary branches, $P = 0.015$; number of dendritic segments, $P = 0.0005$; branching points, $P = 0.001$; maximum length, $P = 0.035$; soma size, $P = 0.0006$; *sum of intersections* $P = 0.02$; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

0.001. **b**, Electrophysiological assessment of AS and ASD cells. Representative traces of multiple action potential discharge after step-current injections in AS (left) and ASD (middle) cells. Action potentials could be reliably blocked by TTX [0.5 μ M] bath application (right). **c**, Micrographs show iGNs treated with Dorsomorphin immunoreactive for TUBB3 and GABA which acquire highly complex neuronal morphology. ASD iGNs show overlapping immunoreactivity for parvalbumin (PVALB) and GABA (n =3). Nuclei are stained with Dapi. Scale bars = 50 μ m. **d**, Biplot showing the expression of *DLX1* and *NEUROG2* in all *SNAP25*-expressing cells. **e**, Monocle plot from Fig. 4g colored based on the expression of genes that show the loss of pericyte marker gene expression along the pseudotime and the acquisition of GABAergic and glutamatergic cell fate determinants along the trajectory towards different neuronal subtypes. **f**, Schematic of ASN experiments. **g**, Micrographs show pericytes transduced with AS (green) and Neurog2 (red) that acquire VGLUT1 immunoreactivity by co-expression of these three transcription factors. Note the punctate appearance of VGLUT1 in inset (right) (n = 3). Nuclei are stained with Dapi. Scale bars = 50 μ m.



Supplementary Figure 5

High-throughput scRNA-seq data from a second pericyte donor confirms lineage bifurcations during iN maturation.

a, scRNA-seq using a high-throughput droplet microfluidic platform (10X genomics) was performed on 3419 AS-transduced cells treated with Dorsomorphin at 14 days post infection. PCA followed by tSNE shows cell populations that maintain pericyte markers (greys) and fail to productively differentiate to a neuronal lineage, populations at intermediate stages of differentiation (light grey), and two distinct neuron populations (cyan, blue). **b**, Cells are colored in the tSNE plots based on log normalized expression of pericyte marker *PDGFRB*, group 1 marker *LEPR*, and neuronal marker *SNAP25*. **c**, The inset shows the log normalized expression of markers for distinct excitatory (*NEUROG2*) and inhibitory (*DLX1*) neuronal populations that emerge during reprogramming. **d**, Heatmap shows the scaled expression of the top 20 genes that are differentially expressed (based on average log fold change) between the two neuronal populations. Single cells are in columns, genes in rows.